<p>英特格拉生命科學最近的財報電話會議呈現出複雜的情緒，反映了運營成功與持續挑戰。公司展示了強大的運營效率和戰略進展，例如關鍵產品的提前重新推出。然而，這些積極因素受到供應鏈中斷、耳鼻喉科和私人標籤業務的挑戰以及下調的全年指引的影響，整體表現呈現出混合的狀態。</p>
<h2>強勁的有機收入增長</h2>
<p>儘管面臨多重挑戰，英特格拉生命科學實現了約 5% 的有機收入同比增長。本季度總收入達到 4.02 億美元，突顯了公司在艱難環境中維持增長的能力。</p>
<h2>調整後的每股收益超出指引</h2>
<p>公司本季度的調整後每股收益為 0.54 美元，超出了指引範圍的上限。這一成就反映了強大的運營效率和有效的成本管理，展示了公司優化運營的能力。</p>
<h2>英特格拉皮膚生產顯著改善</h2>
<p>英特格拉生命科學報告稱，其英特格拉皮膚的生產產量顯著提高，增幅超過 50%。此外，自 1 月以來，庫存水平增加了 2.5 倍，表明公司在生產和庫存管理方面採取了強有力的策略。</p>
<h2>PriMatrix 和 Durepair 的成功重新推出</h2>
<p>PriMatrix 和 Durepair 的提前重新推出，得益於雙重採購策略，增強了公司的供應鏈韌性。這一戰略舉措使公司能夠提前重新引入這些關鍵產品。</p>
<h2>強勁的國際增長</h2>
<p>英特格拉生命科學的國際收入增長了 14.6%，得益於強勁的需求和產品的重新供應。值得注意的是，中國的同比增長達到了 24%，突顯了公司不斷擴大的全球足跡。</p>
<h2>收入低於預期</h2>
<p>儘管整體增長，收入因 CSS 業務的兩次供應中斷和安全庫存水平不足而低於預期。這一短缺突顯了維持供應鏈穩定性所面臨的持續挑戰。</p>
<h2>耳鼻喉科和私人標籤業務的挑戰</h2>
<p>耳鼻喉科業務保持平穩，受到報銷壓力和資本設備採購時機的影響。此外，私人標籤銷售下降了 12.6%，反映出這些領域的挑戰。</p>
<h2>MediHoney 面臨壓力</h2>
<p>由於在合規主計劃下進行的持續整改工作，MediHoney 的銷售受到影響，顯示出該產品線面臨的挑戰。</p>
<h2>下調全年指引</h2>
<p>英特格拉生命科學將 2025 年全年的收入和調整後每股收益指引修訂為 16.2 億至 16.4 億美元和 2.19 至 2.24 美元。這一調整反映了公司的混合表現和持續挑戰。</p>
<h2>毛利率下降</h2>
<p>本季度的毛利率報告為 62.9%，同比下降 10 個基點。這一下降歸因於整改成本和關税的增加，影響了公司的盈利能力。</p>
<h2>前瞻性指引</h2>
<p>展望未來，英特格拉生命科學為 2025 財年提供了更新的指引，預計收入在 16.2 億至 16.4 億美元之間，調整後的每股收益範圍為 2.19 至 2.24 美元。公司仍然專注於執行其合規主計劃，提高運營效率，並保持嚴格的成本管理。他們預計 2026 年將實現適度的收入增長，得益於戰略舉措和預計節省 2500 萬至 3000 萬美元的成本節約措施。</p>
<p>總之，英特格拉生命科學的財報電話會議反映出複雜的情緒，平衡了強大的運營效率和戰略進展與供應鏈和特定業務領域的持續挑戰。儘管面臨這些障礙，公司對未來的增長仍持樂觀態度，得益於戰略舉措和成本節約措施。</p>

英特格拉生命科學

<p>英特格拉生命科學最近的財報電話會議顯示出混合的情緒，展示了運營成功與挑戰並存。公司報告了 5% 的有機收入增長，總收入為 4.02 億美元，調整後的每股收益為 0.54 美元，超出預期。然而，供應鏈中斷以及耳鼻喉科和私人標籤業務的挑戰導致全年指導下調至 16.2 億至 16.4 億美元。儘管毛利率下降至 62.9%，公司預計到 2026 年將實現適度增長，這得益於戰略舉措和節省成本的措施</p>

<p>The recent earnings call for Integra LifeSciences presented a mixed sentiment, reflecting both operational successes and ongoing challenges. The company showcased strong operational efficiency and strategic advancements, such as the early relaunch of key products. However, these positives were tempered by supply chain disruptions, challenges in the ENT and Private Label segments, and a lowered full-year guidance, indicating a mixed performance overall.</p>
<div class="lb-trans"><p>英特格拉生命科學最近的財報電話會議呈現出複雜的情緒，反映了運營成功與持續挑戰。公司展示了強大的運營效率和戰略進展，例如關鍵產品的提前重新推出。然而，這些積極因素受到供應鏈中斷、耳鼻喉科和私人標籤業務的挑戰以及下調的全年指引的影響，整體表現呈現出混合的狀態。</p>
</div><h2>Strong Organic Revenue Growth</h2>
<div class="lb-trans"><h2>強勁的有機收入增長</h2>
</div><p>Despite facing several challenges, Integra LifeSciences achieved an impressive organic revenue growth of approximately 5% year-over-year. The total revenues for the quarter reached $402 million, highlighting the company’s ability to sustain growth even in a challenging environment.</p>
<div class="lb-trans"><p>儘管面臨多重挑戰，英特格拉生命科學實現了約 5% 的有機收入同比增長。本季度總收入達到 4.02 億美元，突顯了公司在艱難環境中維持增長的能力。</p>
</div><h2>Adjusted EPS Exceeds Guidance</h2>
<div class="lb-trans"><h2>調整後的每股收益超出指引</h2>
</div><p>The company’s adjusted EPS for the quarter was $0.54, surpassing the top end of the guidance range. This achievement reflects strong operational efficiency and effective cost management, showcasing the company’s ability to optimize its operations.</p>
<div class="lb-trans"><p>公司本季度的調整後每股收益為 0.54 美元，超出了指引範圍的上限。這一成就反映了強大的運營效率和有效的成本管理，展示了公司優化運營的能力。</p>
</div><h2>Significant Improvement in Integra Skin Production</h2>
<div class="lb-trans"><h2>英特格拉皮膚生產顯著改善</h2>
</div><p>Integra LifeSciences reported a significant improvement in its Integra Skin manufacturing yields, which increased by more than 50%. Additionally, inventory levels have increased by 2.5 times since January, indicating a robust production and inventory management strategy.</p>
<div class="lb-trans"><p>英特格拉生命科學報告稱，其英特格拉皮膚的生產產量顯著提高，增幅超過 50%。此外，自 1 月以來，庫存水平增加了 2.5 倍，表明公司在生產和庫存管理方面採取了強有力的策略。</p>
</div><h2>Successful Relaunch of PriMatrix and Durepair</h2>
<div class="lb-trans"><h2>PriMatrix 和 Durepair 的成功重新推出</h2>
</div><p>The early relaunch of PriMatrix and Durepair, facilitated by a dual sourcing strategy, has improved the company’s supply chain resilience. This strategic move allowed the company to reintroduce these key products ahead of schedule.</p>
<div class="lb-trans"><p>PriMatrix 和 Durepair 的提前重新推出，得益於雙重採購策略，增強了公司的供應鏈韌性。這一戰略舉措使公司能夠提前重新引入這些關鍵產品。</p>
</div><h2>Strong International Growth</h2>
<div class="lb-trans"><h2>強勁的國際增長</h2>
</div><p>International revenue for Integra LifeSciences grew by 14.6%, driven by strong demand and renewed product availability. Notably, China showed a remarkable 24% year-over-year increase, underscoring the company’s expanding global footprint.</p>
<div class="lb-trans"><p>英特格拉生命科學的國際收入增長了 14.6%，得益於強勁的需求和產品的重新供應。值得注意的是，中國的同比增長達到了 24%，突顯了公司不斷擴大的全球足跡。</p>
</div><h2>Revenue Below Expectations</h2>
<div class="lb-trans"><h2>收入低於預期</h2>
</div><p>Despite the overall growth, revenue fell below expectations due to two supply interruptions in the CSS business and insufficient safety stock levels. This shortfall highlights the ongoing challenges in maintaining supply chain stability.</p>
<div class="lb-trans"><p>儘管整體增長，收入因 CSS 業務的兩次供應中斷和安全庫存水平不足而低於預期。這一短缺突顯了維持供應鏈穩定性所面臨的持續挑戰。</p>
</div><h2>Challenges in ENT and Private Label Business</h2>
<div class="lb-trans"><h2>耳鼻喉科和私人標籤業務的挑戰</h2>
</div><p>The ENT business remained flat, affected by reimbursement pressures and the timing of capital equipment purchases. Additionally, Private Label sales saw a decline of 12.6%, reflecting challenges in these segments.</p>
<div class="lb-trans"><p>耳鼻喉科業務保持平穩，受到報銷壓力和資本設備採購時機的影響。此外，私人標籤銷售下降了 12.6%，反映出這些領域的挑戰。</p>
</div><h2>MediHoney Under Pressure</h2>
<div class="lb-trans"><h2>MediHoney 面臨壓力</h2>
</div><p>Sales of MediHoney were impacted due to ongoing remediation efforts under the Compliance Master Plan, indicating the challenges faced in this product line.</p>
<div class="lb-trans"><p>由於在合規主計劃下進行的持續整改工作，MediHoney 的銷售受到影響，顯示出該產品線面臨的挑戰。</p>
</div><h2>Lowered Full Year Guidance</h2>
<div class="lb-trans"><h2>下調全年指引</h2>
</div><p>Integra LifeSciences revised its full-year 2025 revenue and adjusted EPS guidance to $1.62 billion to $1.64 billion and $2.19 to $2.24, respectively. This adjustment reflects the mixed performance and ongoing challenges faced by the company.</p>
<div class="lb-trans"><p>英特格拉生命科學將 2025 年全年的收入和調整後每股收益指引修訂為 16.2 億至 16.4 億美元和 2.19 至 2.24 美元。這一調整反映了公司的混合表現和持續挑戰。</p>
</div><h2>Gross Margin Decline</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>The gross margin for the quarter was reported at 62.9%, a decline of 10 basis points year-over-year. This decrease was attributed to increased remediation costs and tariffs, impacting the company’s profitability.</p>
<div class="lb-trans"><p>本季度的毛利率報告為 62.9%，同比下降 10 個基點。這一下降歸因於整改成本和關税的增加，影響了公司的盈利能力。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>Looking ahead, Integra LifeSciences has provided updated guidance for the fiscal year 2025, with projected revenue between $1.62 billion and $1.64 billion, and an adjusted EPS range of $2.19 to $2.24. The company remains focused on executing its Compliance Master Plan, improving operational efficiency, and maintaining disciplined cost management. They anticipate modest revenue growth in 2026, supported by strategic initiatives and cost-saving measures expected to yield $25 million to $30 million in savings.</p>
<div class="lb-trans"><p>展望未來，英特格拉生命科學為 2025 財年提供了更新的指引，預計收入在 16.2 億至 16.4 億美元之間，調整後的每股收益範圍為 2.19 至 2.24 美元。公司仍然專注於執行其合規主計劃，提高運營效率，並保持嚴格的成本管理。他們預計 2026 年將實現適度的收入增長，得益於戰略舉措和預計節省 2500 萬至 3000 萬美元的成本節約措施。</p>
</div><p>In summary, the earnings call for Integra LifeSciences reflected a mixed sentiment, balancing strong operational efficiencies and strategic advancements with ongoing challenges in supply chain and specific business segments. Despite these hurdles, the company remains optimistic about its future growth, supported by strategic initiatives and cost-saving measures.</p>
<div class="lb-trans"><p>總之，英特格拉生命科學的財報電話會議反映出複雜的情緒，平衡了強大的運營效率和戰略進展與供應鏈和特定業務領域的持續挑戰。儘管面臨這些障礙，公司對未來的增長仍持樂觀態度，得益於戰略舉措和成本節約措施。</p>
</div>

英特格拉生命科學財報電話會議：情緒複雜與戰略進展